Gefarnate

Gefarnate
Skeletal formula
Space-filling model
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • (2E)-3,7-dimethylocta-2,6-dien-1-yl (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.111
Chemical and physical data
FormulaC27H44O2
Molar mass400.647 g·mol−1
3D model (JSmol)
  • CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(C)/CCC=C(C)C
  • InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+ ☒N
  • Key:ZPACYDRSPFRDHO-ROBAGEODSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Gefarnate is a drug used for the treatment of gastric ulcers.[1]

It also has been proposed for use in the treatment of dry eye syndrome.[2][3]

References

  1. ^ Ohta Y, Kobayashi T, Imai Y, Inui K, Yoshino J, Nakazawa S (August 2005). "Effect of gefarnate on acute gastric mucosal lesion progression in rats treated with compound 48/80, a mast cell degranulator, in comparison with that of teprenone". Biol. Pharm. Bull. 28 (8): 1424–30. doi:10.1248/bpb.28.1424. PMID 16079487.
  2. ^ Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J (April 2008). "Therapeutic targets in dry eye syndrome". Drug News Perspect. 21 (3): 166–76. doi:10.1358/dnp.2008.21.3.1203413. PMID 18560615.
  3. ^ Gipson IK, Hori Y, Argüeso P (April 2004). "Character of ocular surface mucins and their alteration in dry eye disease". Ocul Surf. 2 (2): 131–48. doi:10.1016/s1542-0124(12)70149-0. PMID 17216084.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.